Pharma leaders are watching closely as proposed import tariffs of up to 200% raise new questions about cost structures and commercialization strategy.
Beghou CEO Adrienne Lovink’s POV was published in MedCity News where she explores how marketers can prepare for this uncertainty, from trimming SG&A and accelerating omnichannel engagement to exploring alternative distribution paths such as direct-to-consumer sales or telehealth partnerships.